Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
Unknown status
Glaxo Wellcome
Phase 4
1969-12-31
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following
treatments to patients who may not have received anti-HIV treatment: 1) lamivudine
(3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir
(APV)/ritonavir (RTV).
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
Unknown status
Gathe, Joseph, M.D.
N/A
1969-12-31
The purpose of this study is to determine if treatment with an anti-HIV drug containing
ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who
have failed an anti-HIV drug treatment containing nelfinavir.
CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS
(Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI).
The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as
compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different
domains of functioning known to be affected by HIV.
It is hypothesized that participants in the CNS-T arm will have greater improvement in
neurocognitive functioning than those in the non-CNS-T arm.
The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T
HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL).
It is also hypothesized that although CSF viral suppression will be more frequent in the
CNS-T arm, plasma viral suppression will be similar in the two treatment arms.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.